



Complete blood count parameters as biomarkers of retinopathy of prematurity: a Portuguese multicenter study

Mariza Fevereiro-Martins^{1,2,3} · Ana Carolina Santos¹ · Carlos Marques-Neves^{4,5} · Hercília Guimarães⁶ · Manuel Bicho^{1,2} · GenE-ROP Study Group

Received: 27 January 2023 / Revised: 27 January 2023 / Accepted: 11 April 2023 / Published online: 2 May 2023
© The Author(s) 2023

Abstract

Purpose To evaluate complete blood count (CBC) parameters in the first week of life as predictive biomarkers for the development of retinopathy of prematurity (ROP).

Methods Multicenter, prospective, observational study of a cohort of preterm infants born with gestational age (GA) < 32 weeks or birth weight < 1500 g in eight Portuguese neonatal intensive care units. All demographic, clinical, and laboratory data from the first week of life were collected. Univariate logistic regression was used to assess risk factors for ROP and then multivariate regression was performed.

Results A total of 455 infants were included in the study. The median GA was 29.6 weeks, and the median birth weight was 1295 g. One hundred and seventy-two infants (37.8%) developed ROP. Median values of erythrocytes ($p < 0.001$), hemoglobin ($p < 0.001$), hematocrit ($p < 0.001$), mean corpuscular hemoglobin concentration ($p < 0.001$), lymphocytes ($p = 0.035$), and platelets ($p = 0.003$) of the group of infants diagnosed with ROP any stage were lower than those without ROP. Mean corpuscular volume (MCV) ($p = 0.044$), red blood cell distribution width (RDW) ($p < 0.001$), erythroblasts ($p < 0.001$), neutrophils ($p = 0.030$), neutrophils-lymphocytes ratio ($p = 0.028$), and basophils ($p = 0.003$) were higher in the ROP group. Higher values of MCV, erythroblasts, and basophils remained significantly associated with ROP after multivariate regression.

Conclusion In our cohort, the increase in erythroblasts, MCV, and basophils in the first week of life was significantly and independently associated with the development of ROP. These CBC parameters may be early predictive biomarkers for ROP.

Keywords Retinopathy of prematurity · Complete blood count · Biomarker · Preterm infant

✉ Mariza Fevereiro-Martins
martins.mariza@campus.ul.pt

Ana Carolina Santos
carolinasantos@medicina.ulisboa.pt

Carlos Marques-Neves
bombordo.seven@gmail.com

Hercília Guimarães
herciliaguimaraes@gmail.com

Manuel Bicho
manuelbicho@medicina.ulisboa.pt

¹ Laboratório de Genética and Grupo Ecogenética e Saúde Humana, Instituto de Saúde Ambiental (ISAMB), Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, Piso 1C, 1649-028 Lisbon, Portugal

² Instituto de Investigação Científica Bento da Rocha Cabral, Calçada Bento da Rocha Cabral 14, 1250-012 Lisbon, Portugal

³ Departamento de Oftalmologia, Hospital Cuf Descobertas, Rua Mário Botas, 1998-018 Lisbon, Portugal

⁴ Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, Piso 1C, 1649-028 Lisbon, Portugal

⁵ Grupo Ecogenética e Saúde Humana, Instituto de Saúde Ambiental (ISAMB), Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, Piso 1C, 1649-028 Lisbon, Portugal

⁶ Departamento de Ginecologia - Obstetrícia e Pediatria, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Key messages

- Besides the major risk factors for retinopathy of prematurity (ROP), such as low gestational age and low birth weight, also hematological disorders in the neonatal period, mainly anemia and thrombocytopenia, and subsequent blood transfusions, have been associated with ROP.
- In the present study the increase in erythroblasts, mean corpuscular volume (MCV) and basophils of the first week of life was significantly and independently associated with the development of ROP.
- The blood count parameters of premature infants reflect the bone marrow response to perinatal hypoxia and hypoxia, cytokines and growth factors that also influence retinal angiogenesis and may constitute important early biomarkers for ROP.

Abbreviations

BW	Birth weight
CBC	Complete blood count
GA	Gestational age
MCV	Mean corpuscular volume
RDW	Red blood cell distribution width
ROP	Retinopathy of prematurity
VEGF	Vascular endothelial growth factor

Introduction

Retinopathy of prematurity (ROP) is a retinal vasoproliferative disease affecting preterm infants, especially those born with low birth weight [1]. Despite progressive improvements in perinatal care and therapeutic approaches, ROP remains a leading cause of potentially preventable visual impairment and blindness in children worldwide [2]. Blencowe et al. estimated that 184,700 preterm infants developed any stage of ROP in 2010 worldwide, of which 32,000 became blind or mildly/moderately visually impaired due to ROP [3]. Of the latter, 65% were born in middle-income regions [3].

ROP is recognized as a biphasic disease that results from an interruption of the retinal neurovascular development due to preterm birth [4]. In the postnatal period, partial pressure levels of oxygen are higher compared to in utero levels [5]. Suppression of vascular endothelial growth factor (VEGF) due to relative hyperoxia and the loss of maternal–fetal interaction leads to an arrest of retinal vascularization (phase 1) [6]. The generation of reactive oxygen species can cause apoptosis of vascular endothelial cells leading to vaso-obliteration [7]. Subsequently, the increasingly metabolically active retina becomes hypoxic, stimulating vasoproliferation induced by VEGF and other pro-angiogenic growth factors (phase 2), which can lead to retinal detachment [8].

ROP screening guidelines are primarily based on birth weight (BW) and gestational age (GA). However, many studies have suggested other risk factors, including maternal, prenatal, perinatal, genetic, nutritional, demographic, and

others related to medical interventions and comorbidities of prematurity [4, 9–14].

Currently, the diagnosis of ROP and the decision on the need for treatment depend mainly on ophthalmologists with extensive experience in this area, resulting in some subjectivity and variability [15]. The primary screening method for ROP is based on binocular indirect ophthalmoscopy. The wide-field digital retinal imaging system is an alternative method for preliminary screening of ROP or as an adjunct to binocular indirect ophthalmoscopy. An accurate, simple, and reliable diagnostic method for diagnosing ROP has not been found [16]. The development of molecular diagnostic techniques that early identify preterm infants at risk of developing ROP will allow the timely implementation of preventive and therapeutic measures for ROP and a more individualized approach. It would also enable unnecessary evaluation of premature infants to be avoided and would save human resources [17].

In recent years, some parameters obtained from the complete blood count (CBC) of preterm infants have been investigated to find biomarkers of the development of ROP [18–25]. These parameters were generally measured at different time points, and early biomarkers predictive of ROP development have not yet been identified [25].

This study aimed to evaluate the correlation between CBC parameters in the first week of life and the development of ROP in a population of preterm infants.

Methods

Population

This is a multicenter, prospective, observational, and analytical study based on a Portuguese cohort from 8 neonatal intensive care units (Centro Hospitalar Universitário de Lisboa Norte, Hospital Prof. Doutor Fernando Fonseca, Centro Hospitalar Universitário de São João, Centro Materno Infantil do Norte belonging to the Centro Hospitalar Universitário do Porto, Hospital de Braga, Hospital da Senhora da Oliveira—Guimarães, Maternidade Bissaya Barreto,

and Maternidade Daniel de Matos belonging to the Centro Hospitalar Universitário de Coimbra). This is a registered observational study (ISRCTN16889608).

The recruitment period started in a phased manner in the various hospital centers, between 19 November 2018 and 19 December 2019, ending between 30 December 2020 and 21 July 2021.

This study followed from birth the consecutive sampling of preterm infants regardless of sex and race, with at least one of the following characteristics: (1) born before 32 weeks of GA; (2) born with BW of less than 1500 g. The Exclusion criteria were as follows: (1) major congenital malformations in the preterm infant; (2) ophthalmological pathologies, congenital or acquired (during the first 12 weeks of life) not related to ROP except for conjunctivitis, keratitis, and congenital nasolacrimal duct obstruction; (3) death before the first ROP screening; (4) insufficient clinical data due to patient transfer to another hospital; (5) absence of informed consent from parents or legal guardians.

ROP screening and ophthalmological data collection

The first retinal examination was performed at each neonatal intensive care unit by ophthalmologists qualified for ROP screening at 31–33 weeks of postmenstrual age (PMA) or 4 to 6 weeks after birth, whichever was later. The following methods and procedures were used: (1) Adequate mydriasis was obtained through the administration of eye drops according to the guidelines of the latest consensus on ROP of the Portuguese Society of Neonatology [26]; (2) The primary screening was performed by indirect binocular ophthalmoscopy or digital fundus retinography (RetCam) or both, depending on the indication and the hospital center; (3) Examination results were documented for each eye separately according to the criteria of the International ROP Classification (ICROP), published in 1984 [27], and revisited in 2005 [28], and were described in terms of location (zones), the severity of retinopathy (stages), the extent of lesions in the active phase, and the presence or absence of plus disease; (4) Subsequent examinations were determined in each case according to the existence, zone, and severity of ROP and were repeated until complete retinal vascularization or until complete remission of ROP after treatment. Follow-up examinations, the highest ROP stage, and any treatment required were also recorded for both eyes according to the ICROP guidelines [27–29]. The guidelines introduced by the Early Treatment for Retinopathy of Prematurity study (ETROP) [30] were followed regarding the treatment criteria. All patients diagnosed with ROP type 1 were treated with LASER photocoagulation or anti-VEGF, depending on the location of the disease in the retina and the hospital center.

Other data

Demographic, clinical, and laboratory data were collected. CBC from the first week of life was determined according to standardized methods. CBC included erythrocytes ($\times 10^{12}/L$); hemoglobin (g/dL); hematocrit (%); mean corpuscular volume (fl); mean corpuscular hemoglobin concentration (pg); red blood cell distribution width (%); erythroblasts ($\times 10^9/L$); leukocytes ($\times 10^9/L$); neutrophils (%); lymphocytes (%); neutrophils-lymphocytes ratio; basophiles (%); eosinophils (%); platelets ($\times 10^9/L$); and plateletcrit (%). Data related to the objectives were collected from hospital medical records during hospitalization.

Pediatric data included the following: (1) antenatal steroids; (2) birth data: GA, gender, body weight; (3) respiratory data: duration of oxygen administration and mechanical ventilation, need for surfactant therapy; (4) presence of comorbidities such as sepsis, meningitis, bronchopulmonary dysplasia, periventricular and intraventricular hemorrhage, cystic periventricular leukomalacia, patent ductus arteriosus with hemodynamic significance, and necrotizing enterocolitis; (5) number of packed red blood cells, platelets, and serum transfusions received; (6) number of days with hyperglycemia (defined as blood glucose > 125 mg/dL in total blood or > 150 mg/dL in serum) in the first 3 weeks of life.

Statistical analysis

All continuous variables were tested for normality using the Kolmogorov–Smirnov test. Since all were non-normal, median and interquartile range were presented for these tests. In categorical groups, the Mann–Whitney test was used for comparisons between groups. Logistic regression analysis and the corresponding 95% CI were calculated using a binary dependent variable to model the probability of a risk factor for no ROP or ROP or no ROP vs. stages 1 and 2 ROP vs. stage 3 ROP vs. type 1 ROP.

Univariate logistic regression was used to evaluate the risk factors for ROP. The risk factors considered were GA, BW, sex, preeclampsia/eclampsia, gestational diabetes, hyperglycemia, hyaline membrane disease, days of oxygen ventilation, postnatal steroids, red blood cell transfusion, days of red blood cell transfusions, platelet transfusions, days of platelet transfusions, bronchopulmonary dysplasia, persistent ductus arteriosus, periventricular and intraventricular hemorrhage, sepsis, and necrotizing enterocolitis.

After, a multivariate regression (backward conditional) was performed using variables that were significant in univariate and clinically meaningful. Statistical analysis was performed with the SPSS program with a significant value of $p < 0.05$.

Ethics approval

The study protocol, data collection form, and informed consent were approved by the Scientific Council of the Faculty of Medicine of the University of Lisbon and by all scientific councils of participating hospital centers, and by the Ethics Committee of Centro Hospitalar Universitário de Lisboa Norte and Centro Académico de Medicina de Lisboa (CAML) (reference number 340/2018), and Ethics Committees of all other participating hospital centers (Ethics Committee of Hospital da Senhora da Oliveira Guimarães reference number 01/19-CAC, Ethics Committee of Centro Hospitalar Universitário de São João reference number 20–19, Ethics Committee of Hospital Professor Doutor Fernando Fonseca reference number 70/2018, Ethics Committee of Hospital de Braga reference number 15/2019, Ethics Committee of Centro Hospitalar e Universitário de Coimbra reference number CHUC-014–019, Ethics Committee of Centro Hospitalar Universitário do Porto reference number 031-DEFI/032-CE). All collected data is stored and treated as confidential clinical information under the anonymity of the participants. Written informed consent was obtained from the parents of all infants included in the study. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Results

A total of 647 preterm infants were eligible for this study; however, only 461 met the criteria to be included due mainly to death or transfer to other hospitals and consequent follow-up loss (Fig. 1). In this cohort, 455 preterm infants were included, with 230 (50.5%) females. In our study, the incidence of ROP was 37.7%, and no preterm infant developed stage 4 or 5 ROP. A total of 283 (62.3%) preterm infants did not have ROP, stages 1 and 2 represented 133 (29.2%), and stage 3 and type 1 ROP were observed in 18 (3.9%) and 21 (4.6%) preterm infants, respectively (Table 1).

The median of the cohort for the GA was 29.6 weeks and for the BW was 1175.7 g. The median values of GA and BW decreased as the severity of ROP increased (Table 1).

Table 1 includes the clinical characteristics, where it was observed that 416 (91.4%) of the mothers used antenatal steroids, and 219 (48.1%) of preterm infants needed pulmonary surfactant. The red blood cell and platelet transfusion frequency were higher in type 1 ROP, while the plasma transfusions were more frequent in stage 3 ROP. Regarding cell transfusions, red blood cells were more frequent than platelets and plasma.

Regarding prematurity-related diseases, bronchopulmonary dysplasia affected 92 (20.2%) preterm infants of the study population. The need for oxygen ventilation was observed in 402 (88.9%) of the preterm infants, and the

Fig. 1 Flowchart representative of the eligibility and inclusion of preterm infants in the study




Table 1 Demographic and clinical characteristics stratified by stages of ROP

Clinical characteristics, <i>n</i> (%) or median (interquartile range)	Total	No ROP	Stage 1 and stage 2 ROP	Stage 3 ROP	Type 1 ROP	<i>p</i> value
Number of individuals, <i>n</i> (%)	455 (100%)	283 (62.3)	133 (29.2)	18 (3.9)	21 (4.6)	
Gestational age (weeks)	29.6, 3.2	30.4, 2.4	28.4, 3.0	26.4, 2.3	26.1, 2.1	<0.001
Birth weight (g)	1175.7, 445.0	1295.0, 370.0	1050.0, 423.5	850.0, 560.0	755.0, 283.5	<0.001
Gender						0.506
Male	225 (49.5)	147 (51.9)	59 (44.4)	8 (44.4)	11 (52.4)	
Female	230 (50.5)	136 (48.1)	74 (55.6)	10 (55.6)	10 (47.6)	
Bronchopulmonary dysplasia	92 (20.2)	28 (9.9)	39 (29.3)	8 (44.4)	17 (81.0)	<0.001
Necrotizing enterocolitis	26 (5.7)	11 (3.9)	8 (6.0)	6 (33.3)	1 (4.8)	<0.001
Days with glycemia \geq 125 mg/dL	1.0, 3.0	2.0, 3.0	3.0, 5.0	5.0, 6.0	5.0, 4.0	<0.001
Antenatal steroids	416 (91.4)	261 (92.2)	119 (89.5)	16 (88.9)	20 (95.2)	0.802
Pulmonary surfactant	219 (48.1)	92 (32.5)	95 (71.4)	13 (72.2)	19 (90.5)	<0.001
Oxygen ventilation	402 (88.9)	234 (82.7)	129 (97.0)	18 (100.0)	21 (100.0)	0.001
Days of oxygen ventilation	24.0, 46.0	9.0, 31.0	37.0, 44.0	71.0, 53.0	91.0, 46.0	<0.001
Red blood cell transfusions	164 (36.0)	50 (17.7)	79 (59.4)	14 (77.8)	20 (95.2)	<0.001
Days of red blood cell transfusions	2.0, 3.0	1.0, 1.0	2.0, 9.0	4.0, 3.0	5.0, 4.0	<0.001
Platelets transfusions	43 (9.3)	7 (2.5)	26 (19.5)	2 (11.1)	8 (38.1)	<0.001
Days of platelets transfusions	1.0, 1.0	2.0, 1.0	1.0, 1.0	2.0, NA	1.5, 1.0	<0.001
Plasma transfusions	15 (3.3)	2 (0.7)	9 (6.8)	3 (16.7)	1 (4.8)	<0.001
Days of plasma transfusions	1.0, 1.0	1.5, NA	1.0, 0.0	2.0, NA	1.0, 0.0	<0.001

n number of individuals; *p* value, no ROP vs stage 1 + 2 ROP vs stage 3 ROP vs type 1 ROP. NA not applicable

p-value less than 0.05 are in bold

Table 2 Association of parameters of complete blood count with absence or presence of ROP

Parameters of complete blood count (median, interquartile range)	ROP	No ROP	<i>p</i> value	<i>p</i> value [#]	<i>p</i> value*	<i>p</i> value α
Number of individuals, <i>n</i> (%)	172 (37.8)	283 (52.2)	NA	NA	NA	NA
Gestational age (weeks)	28.0, 2.9	30.4, 2.4	<0.001	NA	NA	<0.001
Birth weight (g)	975.0, 410.0	1295.0, 370	<0.001	0.039	0.002	<0.001
Erythrocytes ($\times 10^{12}/L$)	4.0, 0.8	4.3, 0.8	<0.001	0.096	0.502	0.600
Hemoglobin (g/dL)	14.8, 3.5	16.1, 3.4	<0.001	0.215	0.941	0.881
Hematocrit (%)	43.7, 9.8	45.5, 9.1	0.001	0.027	0.207	0.335
Mean corpuscular volume (fl)	108.2, 11.4	107.7, 9.7	0.044	0.023	0.034	0.017
Mean corpuscular hemoglobin concentration (pg)	37.2, 4.2	37.8, 3.5	<0.001	0.685	<0.001	<0.001
Red blood cell distribution width (%)	17.0, 2.9	16.5, 2.2	0.001	0.038	0.001	0.117
Erythroblasts ($\times 10^9/L$)	14.9, 30.6	8.0, 16.7	<0.001	0.037	0.010	0.026
Leukocytes ($\times 10^9/L$)	9.3 (7.0)	9.2 (4.8)	0.599	0.817	0.790	0.225
Neutrophils (%)	42.6, 17.9	41.1, 15.2	0.030	0.681	0.697	0.707
Lymphocytes (%)	37.0, 20.1	40.3, 17.3	0.035	0.902	0.990	0.388
Neutrophils-lymphocytes ratio	1.1, 1.2	0.9, 0.8	0.028	0.682	0.361	0.504
Basophiles (%)	0.7, 0.7	0.5, 0.4	0.003	0.005	0.012	0.004
Eosinophils (%)	1.8 (2.3)	2.1 (2.5)	0.132	0.120	0.143	0.116
Platelets ($\times 10^9/L$)	201.7, 118.0	222.7, 104.7	0.003	0.044	0.005	0.054
Plateletcrit (%)	0.2, 0.1	0.2, 0.1	0.001	0.919	0.864	0.891

n number of individuals; *p* value[#]—adjusted for gestational age and days of red blood cell transfusions. NA not applicable; *p* value*—adjusted for gestational age; *p* value α —adjusted for days of red blood cell transfusions

p-value less than 0.05 are in bold

number of days of oxygen ventilation was higher in the stage 3 and type 1 ROP (Table 1).

Table 2 shows the association between parameters of CBC in preterm infants without or with ROP. Various parameters of the CBC were associated with the development of ROP.

Regarding erythrocyte parameters, the increase in mean corpuscular volume (MCV) and erythroblasts was significantly associated with the group that later developed ROP, even after adjusting for gestational age and number of days of red blood cell transfusion, risk factors determined by the multivariate regression.

Other parameters related to the erythrocyte lineage, such as the decrease in erythrocytes, hemoglobin, hematocrit, and MCHC, were shown to be associated with the development of ROP; however, they were statistically dependent on gestational age and/or days of red blood cell transfusions. Likewise, higher red blood cell distribution width (RDW) was significantly associated with developing ROP but dependent on days of red blood cell transfusions.

On the other hand, increased basophils were significantly associated with developing ROP in logistic regression analysis.

Neutrophilia, lymphopenia, and increased neutrophil-to-lymphocyte ratio were associated with the development of ROP, but the result was not statistically significant in regression analysis.

Thrombocytopenia was a risk factor for developing ROP, but dependent on days of red blood cell transfusions.

Discussion

In the present study, the incidence of ROP at any stage was 37.7%. The incidence of ROP in studies is variable, even comparing countries with similar neonatal intensive care levels. This is due to the great variability in the study designs, GA of preterm infants included, survival rates, and treatments used [8]. Two other prospective studies with similar inclusion criteria, one in the USA and another in Brazil, had an incidence of ROP of 36.6% (211/576) and 25.9% (91/352), respectively [31, 32]. In another recent Portuguese study, the incidence of ROP was 23.8% [33], which may be because it was a retrospective study (between 2012 and 2020) and involved only two hospital centers.

Low GA and low BW were significant risk factors for the development of ROP (Table 1) in agreement with the results of several other studies [1], confirming the value of these parameters as the main determinants of ROP. Our results also showed that hemoderivative transfusion, BPD, oxygen therapy, surfactant, and number of days with hyperglycemia are significantly associated with the risk of developing ROP

and its progression. The same results were presented in other studies [5, 34–36].

Concerning erythrocyte parameters, we observed that the increase in MCV and erythroblasts was significantly and independently associated with the group that later developed ROP (Table 2).

A significant relationship between most fetal hematological values and GA is described. MCV normally decreases while hematocrit increases with GA [37]. Although in our study the group that developed ROP had a lower mean GA than the group that did not develop ROP, it was observed that the association between the increase in MCV and ROP was statistically significant after adjustment in the logistic regression analysis.

To our knowledge, this is the first study reporting a relationship between increased erythroblasts and the development of ROP. However, an increase in both erythrocyte precursors, such as erythroblasts and reticulocytes, and nucleated erythrocytes generally reflects increased erythropoietic activity. Lubetsky et al. and Niranjana et al. observed that the increase in the nucleated red blood cell count on the first day of life can be used to predict ROP and that it can be associated with intrauterine hypoxia [18, 38]. According to these investigators, this result is presumably due to an increased compensatory erythropoiesis as a consequence of intrauterine hypoxia. Erythropoietin regulates the production of fetal erythrocytes in order to maintain normal erythropoiesis at steady state [39]. Serial measurements of erythropoietin levels in the amniotic fluid have shown that when the fetus becomes hypoxic, the concentration of erythropoietin in the amniotic fluid begins to increase exponentially [39].

Other parameters, such as erythrocytes, hemoglobin, hematocrit, and MCHC, were associated with the development of ROP, but were statistically dependent on gestational age and/or days of red blood cell transfusion. In the study by Ünsal et al., the referred analytical parameters evaluated in the fourth week of life were significantly associated with the development of ROP [40]. In the study by Kurtul et al., there was no association between hemoglobin and hematocrit on the first day of life and ROP [19]. Although, in relation to this last study, fluctuations in blood volume and hematocrit on the first day of life make it difficult to interpret the hematocrit value. In the first several postnatal hours, there is a transudation of plasma volume, reducing blood volume and increasing venous hematocrit, after which blood volume increases [41].

In our study, we also found RDW significantly associated with ROP development but dependent on days of red blood cell transfusions, another important risk factor for the development of ROP [5]. RDW corresponds to the coefficient of variation of red blood cell volume, reflecting the heterogeneity of erythrocyte volume, and this may explain why the

association we found between RDW and ROP is modulated by days of red blood cell transfusions [24].

Other studies showed that increased RDW was associated with the development of ROP. The increase in RDW in the first 2 weeks of life in the study by Çömez et al. and in the fourth week of life in the study by Ünsal et al. was significantly associated with the development of ROP [24, 40]. In the study by Said et al. carried out with children admitted to the Saint Louis Children's Hospital Pediatric Intensive Care Unit, RDW was associated with greater morbidity and mortality [42]. In the course of critical illness, red blood cells acquire metabolic and structural lesions, which can lead to decreased deformability, increased adhesion to the endothelium, increased affinity for oxygen [42, 43], decreased hemoglobin content [42, 44], decreased antioxidant capacity [42, 45], restriction of energy metabolism, and impairment of nitric oxide processing and its role in vascular signaling [42, 46]. For this reason, RDW has been suggested as a possible biomarker for RBC damage of sufficient magnitude to influence critical illness outcome, likely by affecting oxygen supply [42]. The increase in RDW, as it can be a biomarker of the disturbance in the supply of oxygen to tissues, and in particular to the retina, may be predictive for the development of ROP [24].

To the best of our knowledge, we describe for the first time a relationship between basophilia and ROP. The increase in basophils was significantly and independently associated with the development of ROP. Basophils constitute about 1% of human peripheral blood leukocytes and have a short half-life [47]. Like other myeloid lineages, they are produced from hematopoietic stem cells in the bone marrow, circulate in peripheral blood, and are rarely present in tissues unless inflammation occurs [47].

Human basophils when activated by immunologic stimuli produce a restricted profile of cytokines such as IL-4 [48], IL-13 [49], and IL-3 [50] and also pro-angiogenic molecules such as VEGF-A, VEGF-B, angiopoietin 1 (ANGPT1), C-X-C motif chemokine ligand 8 (CXCL8), and hepatocyte growth factor [47]. It is also known that human basophils express on their surface VEGF receptor 2 (VEGFR-2) and the co-receptors neuropilin 1 and neuropilin 2 [51]. These data suggest that angiogenesis can be modulated by human basophils [51, 52]. According to the findings of our study, it is possible that the activation of basophils in the context of inflammation due to factors related to prematurity may play a role in the development of ROP.

In this study, thrombocytopenia in the first week of life was shown to be a risk factor for the development of ROP but dependent on days of red blood cell transfusions. It is presumed that, due to red blood cell transfusions, replacement of fetal hemoglobin by adult hemoglobin with lower affinity for oxygen may result in a higher fraction of dissolved oxygen in plasma and greater exposure of tissues

to oxygen [53]. This may downregulate the production of erythropoietin, an angiogenic and oxygen-regulated growth factor that promotes erythropoiesis and plays a role in thrombopoiesis. Furthermore, increased oxygen delivery to the retina is an important risk factor for ROP [5, 54].

Parrozani et al. observed an association between thrombocytopenia in the first hour of life in preterm infants and type 1 ROP [25]. An association between thrombocytopenia and type 1 ROP was also observed from the first day of life to 36 weeks of postmenstrual age in the study by Cakir et al. and 1 week before laser in the study by Jensen et al. [55, 56]. In the study by Akdogan et al., thrombocytopenia at 1 month, but not on the first day of life, was associated with the development of ROP [23].

Despite recent studies linking thrombocytopenia to ROP, the role of platelets in ROP is still not fully understood. Platelets contain several alpha granules with pro-angiogenic molecules, such as VEGF and IGF-1, and anti-angiogenic molecules, such as endostatin [25, 56]. This compartmentalization of different angiogenic regulators within platelets, which can be selectively released or sequestered in different local environments, may explain how platelets can stimulate or inhibit angiogenesis [25, 56]. Moreover, platelet count is highly correlated with serum levels of VEGF-A and brain-derived neurotrophic factor (BDNF), supporting the hypothesis that platelet count could be used as an indirect measure of platelet-derived levels of these factors [57].

In the first week of life of preterm infants, when we analyzed the platelet count, the retina was still avascular and needed to be more vascularized. It is possible that at this stage platelets may have a more stimulating role in angiogenesis by releasing IGF-1, and that thrombocytopenia may cause an imbalance between the mediators of angiogenesis. Hellgren et al. showed that in preterm infants, maintaining platelet levels and, therefore, platelet-derived growth factors can reduce the risk of developing ROP [57].

Our results suggest that some CBC parameters, beyond their traditional clinical applicability, may be early predictive biomarkers of ROP. Confirmation of these results may allow the integration of these biomarkers in models to calculate the risk of developing ROP. The use of biomarkers and possibly also clinical risk factors in a risk analysis system could potentially allow the development of more appropriate screening and follow-up strategies for preterm infants, depending on their risk level. It could also reduce the amount of ROP screening tests for lower-risk infants, sparing them this discomfort while also saving human resources.

As limitations of this study, it should be noted that, due to its observational nature, CBCs were obtained from routine tests performed on preterm infants or from clinical indications unrelated to the study, in the first week of life, but without defined time points for their performance. Furthermore, as this is a multicenter study, the screening for ROP was performed by experienced ophthalmologists, but different

for each hospital center. As such, the existence of bias due to inter-observer variability cannot be excluded.

More prospective studies with larger cohorts are needed to confirm our results.

In conclusion, we found some parameters of the CBC of the first week of life as possible major early predictive biomarkers of the development of ROP. In particular, the increase in erythroblasts, MCV, and basophils was significantly and independently associated with the development of ROP. These results are encouraging regarding the use of CBC parameters as a widely available and cost-effective screening test that could potentially be integrated into models to provide preliminary guidance to ophthalmologists and neonatologists about infants at risk of developing ROP, which is now more necessary than ever.

Acknowledgements GenE-ROP Study Group

Investigators for this study were at the following institutions:

- Laboratório de Genética and Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal: Mariza Fevereiro-Martins, MD; Ana Carolina Santos, MSc; Conceição Afonso, Tech; Joana Ferreira, BSc; Carlos Marques-Neves, MD, PhD; Manuel Bicho, MD, PhD.

- Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal: Rita Espírito Santo, MD; Filipa Teixeira, MD; Rita Rosa, MD; Cristina Vaz Carneiro, MD; Marta Ferreira, BSc; Teresa Matos, BSc.

- Centro Hospitalar Universitário do Porto, Oporto, Portugal: Luísa Neiva, MD; Sandra Pereira, MD; Sofia Aires, MD; Ricardo Parreira, MD; Zuzana Melnik, MD; João Faria, MD.

- Hospital de Braga, Braga, Portugal: Joana Teixeira, MD; Pedro Barros, MD; Juliana Almeida, MD; Bruna Malheiro, MD; Patrícia Cunha Rodrigues, MD; Luís Albuquerque, MD.

- Hospital da Senhora da Oliveira, Guimarães, Portugal: Alice Freitas, Pedro Barros, MD; Nadezda Kotchekova, MD; Rui Freitas, MD; Ana Cristina Silveira, MD; Ana Ferreira, MD.

- Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal: Benvinda Morais, MD; Susana Teixeira, MD; Mafalda Mota, MD; Maria Guerra, MD; Lúcia Coimbra, MD; João Gigante, MD.

- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal: Muriel Ferreira, MD, MSc; Patrícia Lapa, MD; Madalena Monteiro, MD; Mário Alfaiate, MD; Teresa Rodrigues, MD; Teresa Pina, MD.

- Centro Hospitalar Universitário de São João, Oporto, Portugal: Marta Rosário, MD; Renato Silva, MD; Jorge Breda, MD; Filipa Bazenga, MD; João António Pinto, MD; Hercília Guimarães, MD, PhD.

Author contribution Mariza Fevereiro-Martins and Manuel Bicho had the idea for the article. Mariza Fevereiro-Martins, Manuel Bicho, and Ana Carolina Santos contributed to the conception and design of the article. Mariza Fevereiro-Martins was responsible for data acquisition. Statistical analysis was performed by Ana Carolina Santos. The first version of the manuscript was written by Mariza Fevereiro-Martins and Ana Carolina-Santos. All authors participated in the analysis and interpretation of data. All authors reviewed the article critically for important intellectual content and commented on previous versions. All authors read and approved the final manuscript.

Funding Open access funding provided by FCTIFCCN (b-on). This work was supported by the Laboratório de Genética and the Instituto de Saúde Ambiental (ISAMB) of the Faculdade de Medicina of Universidade de Lisboa and the Instituto de Investigação Científica Bento da Rocha Cabral. The writing of the manuscript was also supported by funds from Fundação para a Ciência e a Tecnologia to ISAMB (ref. UIDB/04295/2020 and UIDP/04295/2020). This work was also part of a doctoral project funding

by the company CUF with a PhD grant in Medicine awarded in 2021 and by the Portuguese Society of Ophthalmology with a PhD grant awarded in 2019. The funding organizations had no role in the design, interpretation of data, or conclusions of this research.

Declarations

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Centro Hospitalar Universitário de Lisboa Norte and Centro Académico de Medicina de Lisboa (CAML), and Ethics Committees of all other participating hospital centers, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from the parents of all infants included in the study. This article does not contain any studies with animals performed by any of the authors.

Conflict of interest The authors (Mariza Fevereiro-Martins, Ana Carolina Santos, Carlos Marques-Neves, Hercília Guimarães, Manuel Bicho) declare no conflicts of interest. Mariza Fevereiro-Martins received a research fund from the company CUF and the Portuguese Society of Ophthalmology for the conduct of the present study. The funding body did not influence the design, data interpretation, or conclusions of this study. No proprietary interest is involved in any author of this manuscript.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF (2018) Retinopathy of prematurity: a review of risk factors and their clinical significance. *Surv Ophthalmol* 63:618–637. <https://doi.org/10.1016/J.SURVOPHTHAL.2018.04.002>
- Darlow BA, Gilbert C (2019) Retinopathy of prematurity - a world update. *Semin Perinatol* 43:315–316. <https://doi.org/10.1053/J.SEMPERI.2019.05.001>
- Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C (2013) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. *Pediatr Res* 74(Suppl 1):35–49. <https://doi.org/10.1038/PR.2013.205>
- Lenhartova N, Matasova K, Lasabova Z, Javorka K, Calkovska A (2017) Impact of early aggressive nutrition on retinal development in premature infants. *Physiol Res* 66:S215–S226. <https://doi.org/10.33549/PHYSIOLRES.933677>
- Hengartner T, Adams M, Pfister RE, Di S, McDougall J, Waldvogel S, Held-Egli K, Spring L, Rogdo B, Riedel T, Arlettaz-Mieth R (2020) Associations between red blood cell and platelet transfusions and retinopathy of prematurity. *Neonatology* 117:562–568. <https://doi.org/10.1159/000512020>
- Ryu J (2022) New aspects on the treatment of retinopathy of prematurity: currently available therapies and emerging novel therapeutics. *Int J Mol Sci* 23(15):8529. <https://doi.org/10.3390/IJMS23158529>

7. Krishna Vadlapatla R, DuttVadlapudi A, Mitra AK (2013) Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. *Curr Drug Targets* 14(8):919–935. <https://doi.org/10.2174/13894501113149990015>
8. Hellström A, Smith LEH, Dammann O (2013) Retinopathy of prematurity. *Lancet (London, England)* 382:1445–1457. [https://doi.org/10.1016/S0140-6736\(13\)60178-6](https://doi.org/10.1016/S0140-6736(13)60178-6)
9. Gagliardi L, Rusconi F, Da Frè M, Mello G, Carnielli V, Di Lallo D, Macagno F, Miniaci S, Corchia C, Cuttini M (2013) Pregnancy disorders leading to very preterm birth influence neonatal outcomes: results of the population-based ACTION cohort study. *Pediatr Res*. <https://doi.org/10.1038/pr.2013.52>
10. Hartnett ME, Morrison MA, Smith S, Yanovitch TL, Young TL, Colaizy T, Momany A, Dagle J, Carlo WA, Clark EAS, Page G, Murray J, DeAngelis MM, Cotten CM (2014) Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants. *Investig Ophthalmol Vis Sci* 55:6194–6203. <https://doi.org/10.1167/iovs.14-14841>
11. Barker L, Bunce C, Husain S, Adams GGW (2017) Is artificial reproductive technology a risk factor for retinopathy of prematurity independent of the generation of multiple births? *Eur J Ophthalmol* 27(2):174–178. <https://doi.org/10.5301/ejo.5000832>
12. Lundgren P, Athikarisamy SE, Patole S, Lam GC, Smith LE, Simmer K (2018) Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity. *Acta Paediatr* 107:759. <https://doi.org/10.1111/APA.14187>
13. Goldstein GP, Leonard SA, Kan P, Koo EB, Lee HC, Carmichael SL (2019) Prenatal and postnatal inflammation-related risk factors for retinopathy of prematurity. *J Perinatol* 39(7):964–973. <https://doi.org/10.1038/s41372-019-0357-2>
14. Reem RE, Nguyen T, Yu Y, Ying G-S, Tomlinson LA, Binensbaum G (2021) Effects of altitude on retinopathy of prematurity. *J Am Assoc Pediatr Ophthalmol Strabismus* 61(7):2190. <https://doi.org/10.1016/j.jaapos.2021.08.254>
15. Kalpathy-Cramer J, Campbell JP, Erdogmus D et al (2016) Plus disease in retinopathy of prematurity: improving diagnosis by ranking disease severity and using quantitative image analysis. *Ophthalmology* 123:2345–2351. <https://doi.org/10.1016/j.ophttha.2016.07.020>
16. Tan W, Li B, Wang Z, Zou J, Jia Y, Yoshida S, Zhou Y (2022) Novel potential biomarkers for retinopathy of prematurity. *Front Med* 9:840030. <https://doi.org/10.3389/FMED.2022.840030>
17. Quinn GE, Vinekar A (2019) The role of retinal photography and telemedicine in ROP screening. *Semin Perinatol* 43:367–374. <https://doi.org/10.1053/J.SEMPERI.2019.05.010>
18. Niranjani HS, Bharath Kumar Reddy KR, Benakappa N, Murthy K, Shivananda S, Veeranna V (2013) Role of hematological parameters in predicting retinopathy of prematurity (ROP) in preterm neonates. *Indian J Pediatr* 80:726–730. <https://doi.org/10.1007/S12098-013-0986-Y>
19. Kurtul BE, Kabatas EU, Zenciroglu A, Ozer PA, Ertugrul GT, Beken S, Okumus N (2015) Serum neutrophil-to-lymphocyte ratio in retinopathy of prematurity. *J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus* 19:327–331. <https://doi.org/10.1016/J.JAPOS.2015.04.008>
20. Tao Y, Dong Y, Lu C-W, Yang W, Li Q (2015) Relationship between mean platelet volume and retinopathy of prematurity. *Graefes Arch Clin Exp Ophthalmol* 253:1791–1794. <https://doi.org/10.1007/S00417-015-2972-8>
21. Hu YX, Xu XX, Shao Y, Yuan G-L, Mei F, Zhou Q, Cheng Y, Wang J, Wu XR (2017) The prognostic value of lymphocyte to monocyte ratio in retinopathy of prematurity. *Int J Ophthalmol* 10:1716. <https://doi.org/10.18240/IJO.2017.11.13>
22. Korkmaz L, Baştuğ O, Özdemir A, Korkut S, Karaca Ç, Akın MA, Öztürk MA (2018) Platelet mass index can be a reliable marker in predicting the prognosis of retinopathy of prematurity in very preterm infants. *Pediatr Neonatol* 59:455–463. <https://doi.org/10.1016/J.PEDNEO.2017.11.001>
23. Akdogan M, Ustundag Y, Cevik SG, Dogan P, Dogan N (2021) Correlation between systemic immune-inflammation index and routine hemogram-related inflammatory markers in the prognosis of retinopathy of prematurity. *Indian J Ophthalmol* 69:2182–2187. https://doi.org/10.4103/IJO.IJO_2745_20
24. Çömez A, Yurttutan S, Seringec Akkececi N, Bozkaya A, Köküsarı G, Evgin İ, İpek S (2021) Red cell distribution width and its association with retinopathy of prematurity. *Int Ophthalmol* 41:699–706. <https://doi.org/10.1007/S10792-020-01627-7>
25. Parrozzani R, Nacci EB, Bini S, Marchione G, Salvadori S, Nardo D, Midena E (2021) Severe retinopathy of prematurity is associated with early post-natal low platelet count. *Sci Rep* 11(1):891. <https://doi.org/10.1038/S41598-020-79535-0>
26. Henriques G, Brito C, Teixeira S (2014) Consenso Clínico Retinopatia da Prematuridade. C. Seção Neonatol Soc Port Pediatr. <https://www.spneonatologia.pt/wp-content/uploads/2016/11/2014-ROP.pdf>. Accessed 12 October 2022
27. (1984) An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. *Arch Ophthalmol (Chicago, Ill 1960)* 102:1130–1134. <https://doi.org/10.1001/ARCHOPHT.1984.01040030908011>
28. Quinn GE (2005) The International Classification of Retinopathy of Prematurity revisited. *Arch Ophthalmol (Chicago, Ill 1960)* 123:991–999. <https://doi.org/10.1001/ARCHOPHT.123.7.991>
29. Fierson WM (2018) Screening examination of premature infants for retinopathy of prematurity. *Pediatrics* 142(6):e20183061. <https://doi.org/10.1542/PEDS.2018-3061>
30. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. *Arch Ophthalmol (Chicago, Ill 1960)* 121:1684–1696. <https://doi.org/10.1001/ARCHOPHT.121.12.1684>
31. Karna P, Muttineni J, Angell L, Karmaus W (2005) Retinopathy of prematurity and risk factors: a prospective cohort study. *BMC Pediatr* 5(1):18. <https://doi.org/10.1186/1471-2431-5-18>
32. Fortes Filho JB, Eckert GU, Procianny L, Barros CK, Procianny RS (2009) Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. *Eye (Lond)* 23:25–30. <https://doi.org/10.1038/SJ.EYE.6702924>
33. Almeida AC, Brízido M, Teixeira S, Coelho C, Borrego LM, Correia M (2022) Incidence and risk factors for retinopathy of prematurity in a Portuguese cohort. *J Pediatr Ophthalmol Strabismus* 59:254–260. <https://doi.org/10.3928/01913913-20220104-01>
34. Ahmadpour-Kacho M, JashniMotlagh A, Rasoulinejad SA, Jahangir T, Bijani A, Zahed Pasha Y (2014) Correlation between hyperglycemia and retinopathy of prematurity. *Pediatr Int* 56:726–730. <https://doi.org/10.1111/PED.12371>
35. Stark A, Dammann C, Nielsen HC, Volpe MAV (2018) A pathogenic relationship of bronchopulmonary dysplasia and retinopathy of prematurity? A review of angiogenic mediators in both diseases. *Front Pediatr* 6:125. <https://doi.org/10.3389/FPED.2018.00125>
36. Coshal H, Mukerji A, Lemyre B, Ng EH, Alvaro R, Ethier G, Yoon EW, Beltempo M, Shah PS (2021) Characteristics and outcomes of preterm neonates according to number of doses of surfactant received. *J Perinatol* 41:39. <https://doi.org/10.1038/S41372-020-00779-9>
37. Geaghan S (1999) Hematologic values and appearances in the healthy fetus, neonate, and child - PubMed. *Diagnostic Pediatr Hematol* 19:1–37
38. Lubetzky R, Stolovitch C, Dollberg S, Mimouni FB, Salomon M, Mandel D (2005) Nucleated red blood cells in preterm infants

- with retinopathy of prematurity. *Pediatrics* 116(5):e619–e622. <https://doi.org/10.1542/PEDS.2005-0915>
39. Teramo KA, Klemetti MM, Widness JA (2018) Robust increases in erythropoietin production by the hypoxic fetus is a response to protect the brain and other vital organs. *Pediatr Res* 84:807. <https://doi.org/10.1038/S41390-018-0054-4>
 40. AkyüzÜnsal Aİ, Key Ö, Güler D, Omurlu İK, Anık A, Demirci B, Dündar S (2020) Can complete blood count parameters predict retinopathy of prematurity? *Turkish J Ophthalmol* 50:87–93. <https://doi.org/10.4274/TJO.GALENOS.2019.45313>
 41. Geaghan SM (1999) Hematologic values and appearances in the healthy fetus, neonate, and child. *Clin Lab Med* 19:1–37
 42. Said AS, Spinella PC, Hartman ME, Steffen KM, Jackups R, Holubkov R, Wallendorf M, Doctor A (2017) Red blood cell distribution width: biomarker for red cell dysfunction and critical illness outcome? *Pediatr Crit Care Med* 18:134. <https://doi.org/10.1097/PCC.0000000000001017>
 43. Ibrahim EEDS, McLellan SA, Walsh TS (2005) Red blood cell 2,3-diphosphoglycerate concentration and in vivo P50 during early critical illness. *Crit Care Med* 33:2247–2252. <https://doi.org/10.1097/01.CCM.0000181675.39370.3D>
 44. Condon MR, Kim JE, Deitch EA, Machiedo GW, Spolarics Z (2003) Appearance of an erythrocyte population with decreased deformability and hemoglobin content following sepsis. *Am J Physiol Heart Circ Physiol* 284(6):H2177–H2184. <https://doi.org/10.1152/AJPHEART.01069.2002>
 45. Rogers SC, Said A, Corcuera D, McLaughlin D, Kell P, Doctor A (2009) Hypoxia limits antioxidant capacity in red blood cells by altering glycolytic pathway dominance. *FASEB J* 23:3159–3170. <https://doi.org/10.1096/FJ.09-130666>
 46. Doctor A, Platt R, Sheram ML, Eischeid A, McMahon T, Maxey T, Doherty J, Axelrod M, Kline J, Gurka M, Gow A, Gaston B (2005) Hemoglobin conformation couples erythrocyte S-nitrosothiol content to O₂ gradients. *Proc Natl Acad Sci U S A* 102:5709–5714. <https://doi.org/10.1073/PNAS.0407490102>
 47. Marone G, Gambardella AR, Mattei F, Mancini J, Schiavoni G, Varricchi G (2020) Basophils in tumor microenvironment and surroundings. *Adv Exp Med Biol* 1224:21–34. https://doi.org/10.1007/978-3-030-35723-8_2
 48. Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Madhur MS, Wymann S, Vonarburg C, Chevailler A, Dimitrov JD, Benveniste O, Bruhns P, Kaveri SV, Bayry J (2019) Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. *J Allergy Clin Immunol* 144:524–535. e8. <https://doi.org/10.1016/J.JACI.2018.10.064>
 49. Schroeder JT, Lichtenstein LM, MacDonald SM (1997) Recombinant histamine-releasing factor enhances IgE-dependent IL-4 and IL-13 secretion by human basophils. *J Immunol* 159:447–452
 50. Schroeder JT, Chichester KL, Bieneman AP (2009) Human basophils secrete IL-3: evidence of autocrine priming for phenotypic and functional responses in allergic disease. *J Immunol* 182:2432–2438. <https://doi.org/10.4049/JIMMUNOL.0801782>
 51. Varricchi G, Loffredo S, Galdiero MR, Marone G, Cristinziano L, Granata F, Marone G (2018) Innate effector cells in angiogenesis and lymphangiogenesis. *Curr Opin Immunol* 53:152–160. <https://doi.org/10.1016/J.COI.2018.05.002>
 52. Marone G, Varricchi G, Loffredo S, Granata F (2016) Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. *Eur J Pharmacol* 778:146–151. <https://doi.org/10.1016/J.EJPHAR.2015.03.088>
 53. Hellström W, Martinsson T, Morsing E, Gränse L, Ley D, Hellström A (2022) Low fraction of fetal haemoglobin is associated with retinopathy of prematurity in the very preterm infant. *Br J Ophthalmol* 106:970. <https://doi.org/10.1136/BJOPHTHALMOL-2020-318293>
 54. Stutchfield CJ, Jain A, Odd D, Williams C, Markham R (2017) Foetal haemoglobin, blood transfusion, and retinopathy of prematurity in very preterm infants: a pilot prospective cohort study. *Eye* 31(10):1451–1455. <https://doi.org/10.1038/eye.2017.76>
 55. Cakir B, Liegl R, Hellgren G, Lundgren P, Sun Y, Klevebro S, Löfqvist C, Mannheimer C, Cho S, Poblete A, Duran R, Hallberg B, Canas J, Lorenz V, Liu ZJ, Sola-Visner MC, Smith LE, Hellström A (2018) Thrombocytopenia is associated with severe retinopathy of prematurity. *JCI insight* 3:1–11. <https://doi.org/10.1172/jci.insight.99448>
 56. Jensen AK, Ying GS, Huang J, Karp K, Quinn GE, Binenbaum G (2011) Thrombocytopenia and retinopathy of prematurity. *J AAPOS* 15:e3. <https://doi.org/10.1016/J.JAPOS.2011.07.006>
 57. Hellgren G, Lundgren P, Pivodic A, Löfqvist C, Nilsson AK, Ley D, Sävman K, Smith LE, Hellström A (2021) Decreased platelet counts and serum levels of VEGF-A, PDGF-BB, and BDNF in extremely preterm infants developing severe ROP. *Neonatology* 118:18–27. <https://doi.org/10.1159/000512282>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.